Previous studies have demonstrated that the activation of the NRF2 pathway contributes to resistance against various anticancer therapies, with early-stage NSCLC patients harboring KEAP1 or NFE2L2 mutations exhibiting a higher risk of local recurrence following radiotherapy [160,161]. Here, NFE2L2 is linked to non-small cell lung carcinoma.